Biotech Viking Therapeutics has gained prominence over the past two years, but it could have plenty of upside left.

Global pharmaceutical company Eli Lilly (NYSE:LLY) reported revenue ahead of Wall Streets expectations in Q3 CY2025, with ...

The results come as Eli Lilly works to maintain its edge over Novo Nordisk in the booming market for a class of obesity and ...

Eli Lilly (LLY) stock rises after reporting that sales of its weight-loss drugs more than doubled in the third quarter. The ...

Mounjaro generated sales of $6.5bn in Q3 2025, up 109% from the same period in 2024. Zepbound exhibited even higher growth – ...

India’s GLP-1 drug market is poised for explosive growth, outpacing global trends and positioning domestic pharma giants to challenge multinational dominance.

Since then, supply has returned thanks to Lilly's investments in manufacturing and a move to also offer Zepbound, previously only sold in injector pens, in single-dose vials -- these are easier and ...

On Oct. 30, Eli Lilly will announce third-quarter earnings results that could lift the stock, or pressure it further. Here ...

The top China executive of US pharmaceutical company Eli Lilly and Co said on Wednesday that the company aims to make its ...

Eli Lilly ( LLY) is expected to see a multi-fold increase in its earnings during its third quarter earnings, which is scheduled for October 29 after markets close. The pharma giant is expected to ...

Eli Lilly and Company is a Strong Buy due to strong growth in obesity and diabetes drugs and pipeline innovation. Learn more ...

Picking a date for a press conference in Puerto Rico in the middle of hurricane season can be risky business. | Eli Lilly has ...